Neurotez, Inc. is a private corporation whose primary goal is to develop a Leptin product as a novel hormone replacement therapy for Alzheimer’s disease (AD) and/or as a preventative for those who are at risk.

Leptin, a naturally occurring human hormone associated with various metabolic effects, has a large number of receptors in memory centers of the brain.  This protein is often present at decreased levels in patients suffering from Alzheimer’s disease, and cognitive deterioration in AD patients correlates strongly with a decline in circulating Leptin levels.  The administration of Leptin inhibits both the production of amyloid beta (Aβ) and also the phosphorylation of tau protein in a variety of in vitro and in vivo systems.  Since Aβ and phospho-tau are widely viewed as two of the key factors in Alzheimer’s disease etiology, Leptin represents a highly attractive, multi-functional therapeutic approach.  Perhaps most tellingly, Neurotez has demonstrated that the administration of Leptin significantly improves cognition across a variety of measures in transgenic mouse models of AD.  Thus, a wide spectrum of preclinical findings strongly supports the likelihood that Leptin augmentation will effectively slow or stop the progression of AD and may even preclude or delay the onset of cognitive decline in pre-impairment individuals.